3.8 Review

Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010-2018

期刊

出版社

MDPI
DOI: 10.3390/ijns9020020

关键词

newborn screening; public health; new conditions

向作者/读者索取更多资源

The Recommended Uniform Screening Panel (RUSP) is a list of conditions suggested by the US Secretary of Health and Human Services for newborn screening. From 2010 to 2022, seven conditions were added to the RUSP, including severe combined immunodeficiency (SCID), critical congenital heart disease (CCHD), glycogen storage disease, type II (Pompe), mucopolysaccharidosis, type I (MPS I), X-linked adrenoleukodystrophy (X-ALD), spinal muscular atrophy (SMA), and mucopolysaccharidosis, type II (MPS II). The implementation of SCID and CCHD screening took 8.6 and 6.8 years, respectively, by programs in all 50 states and three territories. As of December 2022, 37 programs screen for Pompe, 34 for MPS I, 32 for X-ALD, and 48 for SMA. The pace of implementation was fastest for SMA, followed by CCHD, SCID, MPS I, Pompe, and X-ALD, based on the average additional number of NBS programs per year.
The Recommended Uniform Screening Panel (RUSP) is the list of conditions recommended by the US Secretary of Health and Human Services for inclusion in state newborn screening (NBS). During 2010-2022, seven conditions were added to the RUSP: severe combined immunodeficiency (SCID) (2010), critical congenital heart disease (CCHD) (2011), glycogen storage disease, type II (Pompe) (2015), mucopolysaccharidosis, type I (MPS I) (2016), X-linked adrenoleukodystrophy (X-ALD) (2016), spinal muscular atrophy (SMA) (2018), and mucopolysaccharidosis, type II (MPS II) (2022). The adoption of SCID and CCHD newborn screening by programs in all 50 states and three territories (Washington, D.C.; Guam; and Puerto Rico) took 8.6 and 6.8 years, respectively. As of December 2022, 37 programs screen for Pompe, 34 for MPS I, 32 for X-ALD, and 48 for SMA. The pace of implementation based on the average additional number of NBS programs per year was most rapid for SMA (11.3), followed by CCHD (7.8), SCID (6.2), MPS I (5.4), Pompe (4.9), and X-ALD (4.7).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据